Transforming growth factor β (TGF-β) type I receptor (activin receptor–like kinase 5, ALK5) has been identified as a promising target for fibrotic diseases. To find a novel inhibitor of ALK5, the authors performed a high-throughput screen of a library of 420 000 compounds using dephosphorylated ALK5. From primary hits of 1521 compounds, 555 compounds were confirmed. In total, 124 compounds were then selected for follow-up based on their unique structures and other properties. Repeated concentration–response testing and final interference assays of the above compounds resulted in the discovery of a structurally novel ALK5 inhibitor (compound 8) (N-(thiophen 2-ylmethyl)-3-(3,4,5 trimethoxyphenyl)imidazo[1,2β]pyridazin 6-amine) with a low IC50 value of 0.7 µM. Compound 8 also inhibited the TGF-β-induced nuclear translocation of SMAD with an EC50 value of 0.8 µM. Kinetic analysis revealed that compound 8 inhibited ALK5 via mixed-type inhibition, suggesting that it may bind to ALK5 differently than other published adenosine triphosphate site inhibitors.
Massague J.,Blain S. W.,Lo R. S..TGFbeta Signaling in Growth Control, Cancer, and Heritable Disorders.Cell. 2000;103:295-309
2.
Yu L.,Noble N. A.,Border W. A..Therapeutic Strategies to Halt Renal Fibrosis.Curr. Opin. Pharmacol.. 2002;2:177-181
3.
Gordon K. J.,Blobe G. C..Role of Transforming Growth Factor–Beta Superfamily Signaling Pathways in Human Disease.Biochim. Biophys. Acta. 2008;4:197-228
4.
Derynck R.,Zhang Y. E..Smad-Dependent and Smad-Independent Pathways in TGF-Beta Family Signaling.Nature. 2003;425:577-584
5.
de Gouville A. C.,Boullay V.,Krysa G.,Pilot J.,Brusq J. M.,Loriolle F.,Gauthier J. M.,Papworth S. A.,Laroze A.,Gellibert F., et al.Inhibition of TGF-Beta Signaling by an ALK5 Inhibitor Protects Rats from Dimethylnitrosamine-Induced Liver Fibrosis.Br. J. Pharmacol.. 2005;145:166-177
Foletta V. C.,Lim M. A.,Soosairajah J.,Kelly A. P.,Stanley E. G.,Shannon M.,He W.,Das S.,Massague J.,Bernard O..Direct Signaling by the BMP Type II Receptor via the Cytoskeletal Regulator LIMK1.J. Cell. Biol.. 2003;162:1089-1098
8.
Siegel P. M.,Massagué J..Cytostatic and Apoptotic Actions of TGF-Beta in Homeostasis and Cancer.Nat. Rev. Cancer. 2003;3:807-818
9.
Sawyer J. S.,Beight D. W.,Britt K. S.,Anderson B. D.,Campbell R. M.,Goodson T.,Herron D. K.,Li H. Y.,McMillen W. T.,Mort N., et al.Synthesis and Activity of New Aryl- and Heteroaryl-Substituted 5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazole Inhibitors of the Transforming Growth Factor–Beta Type I Receptor Kinase Domain.BioMed. Chem. Lett.. 2004;14:3581-3584
10.
Gellibert F.,de Gouville A. C.,Woolven J.,Mathews N.,Nguyen V. L.,Bertho-Ruault C.,Patikis A.,Grygielko E. T.,Laping N. J.,Hue S..Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl) Benzamide (GW788388): A Potent, Selective, and Orally Active Transforming Growth Factor–Beta Type I Receptor Inhibitor.J. Med. Chem.. 2006;49:2210-2221
11.
Sawyer J. S.,Anderson B. D.,Beight D. W.,Campbell R. M.,Jones M. L.,Herron D.,Lampe J. W.,McCowan J. R.,McMillen W. T.,Mort N., et al.Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor–Beta Type I Receptor Kinase Domain.J. Med. Chem.. 2003;46:3953-3956
12.
Singh J.,Chuaqui C. E.,Boriack-Sjodin P. A.,Lee W. C.,Pontz T.,Corbley M. J.,Cheung H. K.,Arduini R. M.,Mead J. N.,Newman M. N., et al.Successful Shape-Based Virtual Screening: The Discovery of a Potent Inhibitor of the type I TGFbeta Receptor Kinase (TbetaRI).Bioorg. Med. Chem. Lett.. 2003;13:4355-4359
13.
Kim D. K.,Choi J. H.,An Y. J.,Lee H. S..Synthesis and Biological Evaluation of 5-(Pyridin-2-yl)thiazoles as Transforming Growth Factor–Beta Type1 Receptor Kinase Inhibitors.Bioorg. Med. Chem. Lett.. 2008;18:2122-2127
14.
Sawyer J. S.,Beight D. W.,Britt K. S.,Anderson B. D.,Campbell R. M.,Goodson T.,Herron D. K.,Li H. Y.,McMillen W. T.,Mort N., et al.Synthesis and Activity of New Aryl-Heteroaryl-Substituted 5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazole Inhibitors of the Transforming Growth Factor–Beta Type I Receptor Kinase Domain.Bioorg. Med. Chem. Lett.. 2004;14:3581-3584
15.
Gellibert F.,Woolven J.,Fouchet M. H.,Mathews N.,Goodland H.,Lovegrove V.,Laroze A.,Nguyen V. L.,Sautet S.,Wang R., et al.Identification of 1,5-Naphthyridine Derivatives as a Novel Series of Potent and Selective TGF-Beta Type I Receptor Inhibitors.J. Med. Chem.. 2004;47:4494-4506
16.
Bonafoux D.,Chuaqui C.,Boriack-Sjodin P. A.,Fitch C.,Hankins G.,Josiah S.,Black C.,Hetu G.,Ling L.,Lee W. C..2-Aminoimidazoles Inhibitors of TGF-Beta Receptor 1.Bioorg. Med. Chem. Lett.. 2009;19:912-916
17.
Gellibert F.,Fouchet M. H.,Nguyen V. L.,Wang R.,Krysa G.,de Gouville A. C.,Huet S.,Dodic N..Design of Novel Quinazoline Derivatives and Related Analogues as Potent and Selective ALK5 Inhibitors.Bioorg. Med. Chem. Lett.. 2009;19:2277-2281
18.
Huynh Q. K.,Kishore N.,Mathialagan S.,Donnelly A. M.,Tripp C. S..Kinetic Mechanisms of IkappaB-Related Kinases (IKK) Inducible IKK and TBK-1 Differ from IKK-1/IKK-2 Heterodimer.J. Biol. Chem.. 2002;277:12550-12558
19.
Fink S. P.,Mikkola D.,Willson J. K. V.,Markowitz S..TGF- Beta-Induced Nuclear Localization of Smad2 and Smad3 in Smad4 Null Cancer Cell Lines.Oncogene. 2003;22:1317-1323
20.
Friesner R. A.,Banks J. L.,Murphy R. B.,Halgren T. A.,Klicic J. J.,Mainz D. T.,Repasky M. P.,Knoll E. H.,Shelley M.,Perry J. K., et al.Glide: A New Approach for Rapid, Accurate Docking and Scoring: 1. Method and Assessment of Docking Accuracy.J. Med. Chem.. 2004;47:1739-1749
21.
Halgren T. A.,Murphy R. B.,Friesner R. A.,Beard H. S.,Frye L. L.,Pollard W. T.,Banks J. L..Glide: A New Approach for Rapid, Accurate Docking and Scoring: 2.J. Med. Chem.. 2004;47:1750-1759
22.
Bradford M. M..Coomassie Brilliant Blue G-250 Dye-Binding Technique for Determination of Autolytic Protein Breakdown in Euglena gracilis and Comparison to Other Methods of Autolysis Measurement.Anal. Biochem.. 1986;72:248-254
23.
Laemmli U. K..Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4.Nature. 1970;227:680-685
24.
Segel I. H.Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. Wiley-Interscience: New York; 1975:
25.
Copeland R. A.Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. Wiley-Interscience: New York; 2005:
26.
Zhang J. H.,Chung T. D.,Oldenburg K. R..A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.J. Biomol. Screen.. 1999;4:67-73
27.
Lipinski C. A.,Lombardo F.,Dominy B. W.,Feeney P. J..Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings.Adv. Drug Deliv. Rev.. 2001;46:3-26
